Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Viridian Therapeutics, Inc. (VRDN : NSDQ)
 
 • Company Description   
Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.

Number of Employees: 50

 
 • Price / Volume Information   
Yesterday's Closing Price: $13.01 Daily Weekly Monthly
20 Day Moving Average: 266,206 shares
Shares Outstanding: 27.93 (millions)
Market Capitalization: $363.34 (millions)
Beta: 1.12
52 Week High: $22.00
52 Week Low: $9.47
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -16.98% -6.48%
12 Week -30.61% -23.71%
Year To Date -34.19% -19.59%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
221 CRESCENT STREET SUITE 401
-
WALTHAM,MA 02453
USA
ph: 617-272-4600
fax: 760-537-4101
daniel@lifesciadvisors.com http://www.viridiantherapeutics.com
 
 • General Corporate Information   
Officers
Jonathan Violin - President; Chief Executive Officer and Director
Tomas Kiselak - Chairman
Kristian Humer - Chief Financial Officer
Peter Harwin - Director
Arlene Morris - Director

Peer Information
Viridian Therapeutics, Inc. (CORR.)
Viridian Therapeutics, Inc. (RSPI)
Viridian Therapeutics, Inc. (CGXP)
Viridian Therapeutics, Inc. (BGEN)
Viridian Therapeutics, Inc. (GTBP)
Viridian Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92790C104
SIC: 8071
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 27.93
Most Recent Split Date: 11.00 (0.07:1)
Beta: 1.12
Market Capitalization: $363.34 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.83 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.75 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.48
Price/Cash Flow: -
Price / Sales: 210.26
EPS Growth
vs. Year Ago Period: 66.32%
vs. Previous Quarter: 25.76%
Sales Growth
vs. Year Ago Period: -85.11%
vs. Previous Quarter: 0.93%
ROE
03/31/22 - -360.68
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -47.72
12/31/21 - -47.70
09/30/21 - -48.09
Current Ratio
03/31/22 - 12.47
12/31/21 - 14.68
09/30/21 - 15.20
Quick Ratio
03/31/22 - -
12/31/21 - 14.68
09/30/21 - 15.20
Operating Margin
03/31/22 - -5,014.24
12/31/21 - -2,680.16
09/30/21 - -2,545.42
Net Margin
03/31/22 - -5,014.24
12/31/21 - -2,680.16
09/30/21 - -5,037.78
Pre-Tax Margin
03/31/22 - -5,014.24
12/31/21 - -2,680.16
09/30/21 - -5,037.78
Book Value
03/31/22 - 1.95
12/31/21 - 2.48
09/30/21 - 2.23
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©